MedPath

SUNBURST (Success Using Neuromodulation With BURST) Study

Not Applicable
Completed
Conditions
Chronic Pain
Interventions
Device: Burst Stimulation
Device: Tonic Stimulation
Registration Number
NCT02011893
Lead Sponsor
Abbott Medical Devices
Brief Summary

The purpose of the study is to demonstrate the safety and efficacy of the Prodigy system for the treatment of chronic intractable pain of the trunk and/or limbs.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
173
Inclusion Criteria
  • Subject is 22 years of age or older
  • Subject has chronic intractable pain of the trunk and/or limbs
  • Subject has a average score of 60 or higher for average daily overall pain on the Visual Analog Scale (VAS) 7 day pain diary
  • Subject has attempted "best" medical therapy and has tried and failed at least three documented medically supervised treatments (including, but not limited to physical therapy, acupuncture, etc.) and has failed medication treatment from at least two different classes
  • Subject's pain-related medication regimen is stable 4 weeks prior to the baseline evaluation
  • Subject agrees not to add or increase pain-related medication from activation through the 24 week follow-up visit
Exclusion Criteria
  • Subject is currently participating in a clinical investigation that includes an active treatment arm
  • Subject has been implanted with a previous neurostimulation system or participated in a trial period for a neurostimulation system
  • Subject's overall Beck Depression Inventory II Score is >24 or has a score of 3 on question 9 relating to suicidal thoughts or wishes at the screening visit
  • Subject has an infusion pump or any implantable neurostimulator device
  • Subjects with concurrent clinically significant or disabling chronic pain problem that requires additional treatment
  • Subject has an existing medical condition that is likely to require repetitive Magnetic Resonance Imaging (MRI) evaluation in the future (i.e. epilepsy, stroke, multiple sclerosis, acoustic neuroma, tumor)
  • Subject has an existing medical condition that is likely to require the use of diathermy in the future
  • Subject's pain originates from peripheral vascular disease
  • Subject is immunocompromised
  • Subject has documented history of allergic response to titanium or silicone
  • Subject has a documented history of substance abuse (narcotics, alcohol, etc.) or substance dependency in the 6 months prior to baseline data collection
  • Female candidates of child bearing potential that are pregnant (confirmed by positive urine/blood pregnancy test)

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Burst StimulationBurst StimulationBurst Stimulation using the Prodigy system
Tonic StimulationTonic StimulationTonic Stimulation using the Prodigy system
Primary Outcome Measures
NameTimeMethod
Visual Analog Scale (VAS) Pain Diary Scores for Average Overall PainOver 7 days after 3 months of treatment of burst or tonic stimulation

Differences for average daily overall pain using the Visual Analog Scale (VAS) pain diary between Burst and Tonic Stimulation. Visual Analog Scale (VAS) scores were averaged using a 7 day diary where the subject rates his/her pain on a horizontal line, from 0 mm to 100mm in length, anchored by word descriptors on each end (no pain to worst imaginable pain). A higher score indicates a higher level of pain.

Secondary Outcome Measures
NameTimeMethod
Percentage of Paresthesia CoverageDuring in-office visit after 3 months of treatment while utilizing burst or tonic stimulation

Paresthesia mapping (percentage of paresthesia coverage) analyzed to demonstrate the differences between Burst and Tonic Stimulation. Data is presented as areas of paresthesia reported while utilizing either Burst or Tonic Stimulation as a percentage of the total number of areas possible.

Number of Subjects With Response as Measured by Overall Daily Visual Analog Scale (VAS)Over 7 days at baseline and after 3 months of treatment of burst or tonic stimulation

Number of subjects responding to Burst and Tonic Stimulation defined as 30% or greater decrease in overall Visual Analog Scale (VAS) score from baseline. Visual Analog Scale (VAS) scores were averaged using a 7 day diary where the subject rates his/her pain on a horizontal line, 100mm in length, anchored by word descriptors on each end (no pain to worst imaginable pain). A higher score indicates a higher level of pain.

Test for Superiority of Overall Daily Visual Analog Scale (VAS) Score With Burst StimulationOver 7 days after 3 months of treatment of burst or tonic stimulation

Differences for average daily overall pain using the Visual Analog Scale (VAS) pain diary between Burst and Tonic Stimulation to evaluate for superiority of Burst Stimulation. Differences for average daily overall pain using the Visual Analog Scale (VAS) pain diary between Burst and Tonic Stimulation. Visual Analog Scale (VAS) scores were averaged using a 7 day diary where the subject rates his/her pain on a horizontal line, 100mm in length, anchored by word descriptors on each end (no pain to worst imaginable pain). A higher score indicates a higher level of pain.

Trial Locations

Locations (20)

Eisenhower Desert Orthopedic Center

🇺🇸

Rancho Mirage, California, United States

Jackson Pain Center

🇺🇸

Jackson, Mississippi, United States

Utah Spine Care

🇺🇸

Ogden, Utah, United States

The Center for Pain Relief

🇺🇸

Charleston, West Virginia, United States

Houston Pain Centers

🇺🇸

Houston, Texas, United States

Goodman Campbell Brain and Spine

🇺🇸

Indianapolis, Indiana, United States

Oklahoma Pain Physicians

🇺🇸

Oklahoma City, Oklahoma, United States

Napa Biomedical Services

🇺🇸

Napa, California, United States

Newport Beach Headache and Pain

🇺🇸

Mission Viejo, California, United States

IPM Medical Group

🇺🇸

Walnut Creek, California, United States

The Neuroscience Center

🇺🇸

Biloxi, Mississippi, United States

The Montana Center for Wellness & Pain Management

🇺🇸

Kalispell, Montana, United States

Bronson Neuroscience Center

🇺🇸

Kalamazoo, Michigan, United States

Midwest Neurosurgery Associates

🇺🇸

Kansas City, Missouri, United States

Comprehensive Pain & Rehabilitation

🇺🇸

Pascagoula, Mississippi, United States

Albany Medical Center

🇺🇸

Albany, New York, United States

NeuroSpine Institute

🇺🇸

Eugene, Oregon, United States

New York Spine & Wellness Center

🇺🇸

North Syracuse, New York, United States

St. Luke's Hospital

🇺🇸

Bethlehem, Pennsylvania, United States

Clinical Trials of South Carolina

🇺🇸

North Charleston, South Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath